Back to Search
Start Over
EE140 Estimated Costs for All-Cause Grade 3/4 Adverse Events Among First-Line Tyrosine Kinase Inhibitor Plus Immuno-Oncology-Based Combination Therapies for Patients with Advanced Renal Cell Carcinoma from the United States Perspective.
- Source :
-
Value in Health . 2022 Supplement, Vol. 25 Issue 7, pS361-S361. 1p. - Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 10983015
- Volume :
- 25
- Issue :
- 7
- Database :
- Academic Search Index
- Journal :
- Value in Health
- Publication Type :
- Academic Journal
- Accession number :
- 157695415
- Full Text :
- https://doi.org/10.1016/j.jval.2022.04.390